ライフサイエンスコーパス: PIV3

1 nd protected against challenge with wt human PIV3.

2 als and may provide novel approaches against PIV3.

3 sue culture, like its PIV1 parent but unlike PIV3.

4 for clinical therapeutic development against PIV3.

5 cross-neutralizing ability against PIV1 and PIV3.

6 y allow a better antiviral regimen targeting PIV3.

7 ld; 226 children (59%) were seronegative for PIV3.

8 ell target antigens, precluding extension to PIV3.

9 ough 5 after inoculation with 10(5.5) pfu of PIV3.

10 e attenuated PIV3 vaccine candidate into the PIV3-1 cDNA followed by recovery of attenuated derivativ

11 icular somatitis virus or measles virus, the PIV3-1 chimera replicates in LLC-MK2 cells and in the re

12 inding monoclonal antibody (mAb), designated PIV3-23, exhibited functional attributes including haema

13 this decrease was in parainfluenza virus 3 (PIV3) (8.3% to 2.2%, P < .001).

14 growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negative-strand RNA virus of the P

15 emonstrated that parainfluenza virus type 3 (PIV3), a significant respiratory pathogen, can markedly

16 of beta-defensins, with mild accentuation of PIV3 activity and inflammation.

17 d body temperature late in the course of the PIV3-adenovirus HBD6 infection.

18 and sheep beta-defensin 1 were increased by PIV3 and adenovirus treatment, and the increased levels

19 to those for the group infected with PIV3 or PIV3 and adenovirus, with an increased respiration rate

20 vaccination of infants and children against PIV3 and other viruses.

21 r levels of immunohistochemical staining for PIV3 and syncytial cell formation than the group infecte

22 parainfluenza virus 1 to 3 (PIV1, PIV2, and PIV3), and adenovirus (AdV) infections.

23 ial virus (RSV), parainfluenza virus type 3 (PIV3), and rhinovirus (RV) 14 were potent stimulators wh

24 (88.9%) of 9 for PIV2, 17 (30.1%) of 55 for PIV3, and 101 (76.5%) of 132 for AdV.

25 eally (it) in the presence of high levels of PIV3 antibodies, replicated efficiently in the nasophary

26 of very high titers of passively transferred PIV3 antibodies.

27 ved in the presence of passively transferred PIV3 antibodies.

28 prehensive studies revealed that these swine PIV3 are variants of bPIV3 and were possibly transferred

29 achieved by using recombinant wild-type (wt) PIV3 as the recipient for PIV1 HN and F, engineered so t

30 ull-length PIV2 glycoproteins in a wild-type PIV3 backbone.

31 otypes observed for r-bPIV3 and bovine/human PIV3, both of these viruses protected hamsters completel

32 idase (HN) proteins from an otherwise bovine PIV3 (bPIV3) genome was employed as a vector for RSV ant

33 ith a hamster model showed that bovine/human PIV3 can be employed to generate bivalent PIV3/RSV or PI

34 a high level of resistance to replication of PIV3 challenge virus in hamsters and induced very high l

35 o protect hamsters from subsequent wild-type PIV3 challenge.

36 live-attenuated human parainfluenza virus 3 (PIV3) cold-passage 45 (cp45) candidate vaccine was shown

37 ion of live attenuated parainfluenza type 3 (PIV3)-cold passage mutant 45 (cp45) vaccine was conducte

38 Previous studies indicated that the PIV3 cp45 virus, a more attenuated version of rcp45L, re

39 pes of the human parainfluenza virus type 3 (PIV3) cp45 live attenuated vaccine candidate.

40 Modest reductions in the shedding of PIV3-cp45 vaccine virus were found after the administrat

41 PIV3-cp45 vaccine was safe and immunogenic in seronegati

42 the 226 seronegative children, 114 received PIV3-cp45 vaccine, and 112 received placebo.

43 r the administration of RSV cpts-248/404 and PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine;

44 RSV cpts-248/404 and PIV3-cp45 vaccines were combined in a dose of 10(5) plaq

45 f 21 children given combination vaccine shed PIV3-cp45 versus 11 (92%) of 12 of those given monovalen

46 e (HN) protein, a structural glycoprotein of PIV3 critical for viral infection and egress.

47 n and transmembrane domain were fused to the PIV3 cytoplasmic domain, and rPIV3-2TM, in which the PIV

48 y coinfection with an IFIT1-resistant virus (PIV3), demonstrating that PIV3 does not specifically inh

49 rrent topical immunotherapy with antibody to PIV3, did not lead to a rebound of viral replication.

50 1-resistant virus (PIV3), demonstrating that PIV3 does not specifically inhibit the antiviral activit

51 iated with a reduction in RVIs, particularly PIV3, during the most vulnerable period following HSCT.

52 terize the cellular immune response to all 7 PIV3-encoded antigens in 17 healthy donors and define a

53 African green monkeys immunized with b/h PIV3 expressing either the native or soluble RSV F prote

54 The recombinant PIV3 expressing the RSV G ORF (rB/HPIV3-G1) was not rest

55 vine/human (b/h) parainfluenza virus type 3 (PIV3) expressing the human PIV3 (hPIV3) fusion (F) and h

56 Th1-polarized effector cytokines and killing PIV3-expressing targets.

57 ecovery of human parainfluenza virus type 3 (PIV3) from cDNA, together with the availability of a pro

58 The PIV3 fusion (F) glycoprotein was trafficked exclusively

59 t several ISG proteins that strongly inhibit PIV3 growth, the use of which may allow a better antivir

60 suggests that this intranasally administered PIV3(HA) chimeric virus can be used to immunize infants

61 f the wild-type or cold-passaged 45L (cp45L) PIV3(HA) chimeric viruses replicated 5- to 10-fold less

62 The attenuated cp45L PIV3(HA) recombinants induced a high level of resistance

63 The group infected with adenovirus HBD6 and PIV3 had increased levels of pulmonary neutrophil recrui

64 ttenuated bovine parainfluenza virus type 3 (PIV3), harboring the fusion (F) and hemagglutinin-neuram

65 be employed to generate bivalent PIV3/RSV or PIV3/hMPV vaccine candidates that will be further evalua

66 Three epitopes on PIV3 HN were delineated and one epitope, Site 2, elicits

67 nza virus type 3 (PIV3) expressing the human PIV3 (hPIV3) fusion (F) and hemagglutinin-neuraminidase

68 to estimate the biologic half-life of human PIV3 (hPIV3) maternal antibody in young infants.

69 IgA antibody titers against bPIV3 and human PIV3 (hPIV3) were measured.

70 racts of nonhuman primates compared to human PIV3 (HPIV3), an important pathogen of infants and young

71 ranasal vaccine for protection against human PIV3 (hPIV3).

72 nza virus types 1, 2, and 3 (PIV1, PIV2, and PIV3), human metapneumovirus (MPV), and adenovirus (AdV)

73 These findings advance our understanding of PIV3 immunity and underscore the significance of targeti

74 ength HN and F proteins of PIV1 for those of PIV3 in the attenuated cp45 PIV3 vaccine candidate.

75 icates that the genetic basis for the CPE of PIV3 in tissue culture lies outside regions encoding the

76 t several other such proteins also inhibited PIV3, including IFITM1, IDO (indoleamine 2,3-dioxygenase

77 -defensin 6 (HBD6) would diminish concurrent PIV3 infection in neonatal lambs.

78 and used this virus, rgPIV3, to characterize PIV3 infection of an established in vitro model of human

79 was carrying a target gene, exacerbated the PIV3 infection.

80 wever, its use during parainfluenza virus 3 (PIV3) infection has not been evaluated.

81 Parainfluenza virus type 3 (PIV3) infection led to laryngotracheitis in cotton rats.

82 Parainfluenza virus 3 (PIV3) infection poses a substantial risk to vulnerable g

83 o play an important immunoregulatory role in PIV3 infections.

84 Parainfluenza virus type 3 (PIV3) infections are a major cause of morbidity and mort

85 ogous glycoproteins were compatible with the PIV3 internal proteins.

86 F glycoproteins in the background of the wt PIV3 internal proteins.

87 b/h PIV3 is suited for development of pediatric vaccines sin

88 Parainfluenza virus type 3 (PIV3) is major pathogen of children, and no reliable vac

89 ization of the HN and F proteins of PIV2 and PIV3 itself specified an attenuation phenotype in vivo.

90 ytial virus (RSV) and parainfluenza 3 virus (PIV3) live, attenuated intranasal vaccine for safety, vi

91 glycoprotein, in order to create a bivalent PIV3-measles virus that can be administered intranasally

92 cell proliferation and protects T cells from PIV3-mediated apoptosis.

93 euraminidase or fusion glycoprotein of human PIV3 (modified vaccinia virus Ankara [MVA]/PIV3 recombin

94 o cells, sG did not reduce the serum RSV- or PIV3-neutralizing antibody (NAb) responses, whereas abla

95 pen reading frame is flanked by the existing PIV3 nontranslated regions and transcription signals.

96 attenuated due to the presence of the bovine PIV3 nucleocapsid (N) protein open reading frame (ORF) i

97 raminidase (HN)-L gene junction of wild-type PIV3 or into the N-P or P-M gene junction of an attenuat

98 ompared to those for the group infected with PIV3 or PIV3 and adenovirus, with an increased respirati

99 LLC-MK2 cultures which resembles that of its PIV3 parent but differs from that of its noncytopathic P

100 t of hamsters as efficiently as its PIV1 and PIV3 parents.

101 Viable PIV3-PIV2 chimeras were recovered when chimeric HN and F

102 PIV3 was required for successful recovery of PIV3-PIV2 chimeras.

103 ns provides a means to further attenuate the PIV3-PIV2 chimeric vaccine candidates if necessary.

104 y, we failed to recover recombinant chimeric PIV3-PIV2 isolate carrying the full-length PIV2 glycopro

105 cation for parainfluenza virus (PIV) type 2, PIV3, PIV5, and mumps virus, as well as on the relative

106 ells with parainfluenza virus type 2 (PIV2), PIV3, PIV5, or mumps virus and determined the abundances

107 didate consisting of a chimeric bovine/human PIV3 (rB/HPIV3) strain expressing the RSV fusion (F) pro

108 attenuated chimeric recombinant bovine/human PIV3 (rB/HPIV3) vector expressing the RSV fusion (F) gly

109 A chimeric bovine/human PIV3 (rB/HPIV3) virus expressing the unmodified, wild-ty

110 was the attenuated recombinant bovine/human PIV3 (rB/HPIV3), a recombinant BPIV3 in which the bovine

111 irus type 3 (rB/HPIV3), a recombinant bovine PIV3 (rBPIV3) in which the F and HN genes were replaced

112 he ts, att, and ca phenotypes of cp45, seven PIV3 recombinant viruses (three single, three double, an

113 n PIV3 (modified vaccinia virus Ankara [MVA]/PIV3 recombinants)-were evaluated in rhesus monkeys to d

114 The recombinant PIV3 (rPIV3) viruses bearing the HA inserts replicated m

115 an PIV3 can be employed to generate bivalent PIV3/RSV or PIV3/hMPV vaccine candidates that will be fu

116 virus members of the paramyxoviridae such as PIV3, Sendai virus (SeV), and canine distemper virus (CD

117 ctly inhibited by IFIT1, the translations of PIV3, SeV, and CDV mRNAs were not.

118 a direct correlation between the presence of PIV3-specific T cells and viral control in allogeneic he

119 er, our findings support the clinical use of PIV3-specific T cells produced with our Good Manufacturi

120 cell formation than the group infected with PIV3, suggesting that treatment with the adenovirus vect

121 gene junction of an attenuated derivative of PIV3, termed rcp45L.

122 In this study, the ability of bovine/human PIV3 to express three different foreign transmembrane su

123 ames (ORFs) were placed under the control of PIV3 transcription signals and inserted individually int

124 and B were each placed under the control of PIV3 transcription signals and inserted individually or

125 n which the PIV2 ectodomain was fused to the PIV3 transmembrane and cytoplasmic tail domain, possesse

126 ating mutations present in a live attenuated PIV3 vaccine candidate into the PIV3-1 cDNA followed by

127 IV1 for those of PIV3 in the attenuated cp45 PIV3 vaccine candidate.

128 b/h PIV3 vaccine candidates expressing native or soluble RSV

129 mising, highly characterized live attenuated PIV3 vaccine virus, suggested a novel strategy for the r

130 sus 11 (92%) of 12 of those given monovalent PIV3 vaccine.

131 nd PIV3-cp45 vaccine, relative to monovalent PIV3 vaccine; 16 (76%) of 21 children given combination

132 Two parainfluenza virus type 3 (PIV3) vaccine candidates-cp45, a live attenuated derivat

133 phase 2 trial of parainfluenza virus type 3 (PIV3) vaccine, sequential serum samples were obtained fr

134 (F) envelope glycoproteins, of an attenuated PIV3 variant are replaced by those of PIV1 or PIV2.

135 e of paramyxoviruses was exploited using the PIV3 vector by inserting the foreign viral genes at the

136 The PIV3-vectored RSV vaccines evaluated here further unders

137 Thus, chimeric recombinant bovine-human PIV3 viruses that manifest different levels of attenuati

138 The replication of bovine/human PIV3 was also restricted in the lungs of hamsters, albei

139 oplasmic tail of the HN or F glycoprotein of PIV3 was required for successful recovery of PIV3-PIV2 c

140 The resulting bovine/human PIV3 was temperature sensitive for growth in Vero cells

141 ecombinant human parainfluenza virus type 3 (PIV3) was used as a vector to express the major protecti

142 agglutinin-neuraminidase (HN) genes of human PIV3, was used as a virus vector to express surface glyc

143 We found that IFIT1 significantly inhibited PIV3, whereas IFIT2, IFIT3, and IFIT5 were less effectiv

144 meric bovine/HPIV3 (B/HPIV3) based on bovine PIV3, with fusion (F) and hemagglutinin-neuraminidase su

145 conferred protection against replication of PIV3 wt challenge virus, but this was largely abrogated